Obliterative bronchiolitis – Diagnostics – Overview of Information and Clinical Research

Understanding obliterative bronchiolitis starts with knowing when to seek medical attention. Early recognition of breathing problems, especially after exposure to harmful substances or serious infections, can make a significant difference in managing this rare but serious lung condition that affects the smallest airways.

Introduction: Who Should Undergo Diagnostics

Obliterative bronchiolitis, also known as bronchiolitis obliterans or constrictive bronchiolitis, is a rare lung disease that affects the smallest airways in the lungs called bronchioles. These tiny tubes become inflamed and then scarred, leading to narrowing and sometimes complete blockage. Because this condition can lead to permanent lung damage, knowing when to seek diagnostic testing is extremely important.^[1]^[2]

People who have undergone lung or bone marrow transplants should be especially vigilant about regular diagnostic monitoring. More than half of all lung transplant recipients will develop some degree of this condition within five years after their transplant, with the average diagnosis occurring between 16 and 20 months after the procedure. For those who have received bone marrow transplants, about 5 to 14 percent may develop the disease, sometimes appearing months or even years later.^[2]^[3]

Workers who are exposed to certain chemicals in their workplace should seek diagnostic testing if they develop persistent breathing problems. Those who work in environments where diacetyl is used—such as microwave popcorn factories, coffee roasting plants, or flavoring manufacturing—are at higher risk. The condition earned the nickname “popcorn lung” after workers in a popcorn factory developed the disease from breathing in diacetyl, a chemical used to create buttery flavoring.^[3]^[5]

Children who have recently recovered from a severe respiratory infection should be monitored carefully. Viruses such as respiratory syncytial virus, adenovirus, or influenza can cause lung injury that leads to bronchiolitis obliterans, especially in young children. Parents should seek medical attention if their child continues to have breathing difficulties, persistent cough, or wheezing weeks after an infection has seemingly cleared.^[6]^[7]

People with autoimmune disorders, particularly rheumatoid arthritis or lupus, should discuss screening with their healthcare provider. These conditions can cause the immune system to attack the body’s own lung tissue, potentially leading to bronchiolitis obliterans. Similarly, anyone who has been exposed to toxic fumes—such as ammonia, chlorine, nitrogen oxides, or sulfur dioxide—should seek evaluation if they experience ongoing respiratory symptoms.^[5]^[7]

⚠️ Important

Sometimes people with obliterative bronchiolitis do not have symptoms initially. The disease can develop slowly, with symptoms appearing weeks or even months after the initial injury to the lungs. This is why it is essential to seek diagnostic testing even if you only have mild symptoms but belong to one of the high-risk groups mentioned above.

Classic Diagnostic Methods

Diagnosing obliterative bronchiolitis can be challenging because the symptoms are similar to other lung conditions such as asthma or chronic obstructive pulmonary disease. Doctors must use several different tests to properly identify the disease and rule out other possible causes.^[4]

Medical History and Physical Examination

The diagnostic process typically begins with a thorough medical history and physical examination. Your doctor will ask detailed questions about your symptoms, when they started, and whether they have been getting worse over time. They will want to know about any recent infections, workplace exposures to chemicals or fumes, history of transplant surgery, or autoimmune conditions. During the physical exam, the doctor will listen to your lungs with a stethoscope. People with obliterative bronchiolitis may have early inspiratory crackles, which are crackling sounds heard when breathing in, or inspiratory “squeaks.” However, some people may have completely normal chest sounds, which is why additional testing is necessary.^[14]

Chest X-ray

A chest X-ray is often one of the first imaging tests performed, but it is frequently normal in people with obliterative bronchiolitis or may only show hyperinflation, which is when the lungs appear overly expanded. Because a normal chest X-ray does not rule out the disease, more detailed imaging is usually needed.^[4]^[14]

High-Resolution Computed Tomography (CT) Scan

The high-resolution CT scan is one of the most important diagnostic tools for obliterative bronchiolitis. This test takes very detailed pictures of the lungs and can show patterns that are characteristic of the disease. The CT scan should be performed during both breathing in (inspiration) and breathing out (expiration) because certain changes are only visible when the patient exhales.^[6]^[14]

The expiratory high-resolution CT scan often shows a distinctive “mosaic pattern” or “mosaic attenuation.” This pattern looks like a patchwork of lighter and darker areas in the lungs. The darker areas represent parts of the lung that are trapping air because the small airways are blocked. The scan may also show bronchiectasis (widening of the airways), air trapping, and thickening of the bronchial walls. In someone with the right symptoms and history, such as being a non-smoker without asthma, this mosaic pattern on the expiratory CT scan can be diagnostic and may eliminate the need for a lung biopsy.^[4]^[14]

Pulmonary Function Testing (Spirometry)

Pulmonary function tests, especially spirometry, measure how well your lungs are working. During spirometry, you breathe into a machine that measures how much air you can exhale and how quickly you can do it. Obliterative bronchiolitis causes an obstructive pattern, meaning that air has difficulty flowing out of the lungs. Unlike asthma, this obstruction does not improve with bronchodilator medications (inhalers that open up the airways), which helps distinguish obliterative bronchiolitis from reversible airway diseases.^[2]^[3]

In children younger than five or six years old, standard spirometry may not be possible because it requires cooperation and the ability to follow instructions. In these cases, doctors may use an infant pulmonary function test, which measures lung function while the child is sedated or asleep.^[6]

Lung Biopsy

A lung biopsy involves removing a small sample of lung tissue to examine under a microscope. This is the most definitive way to diagnose obliterative bronchiolitis, but it is not always necessary if the CT scan findings are clear enough. When a biopsy is performed, doctors look for specific changes in the bronchioles, including fibrosis (scarring) that surrounds and narrows the airways in a concentric pattern. The scarring preferentially affects the membranous bronchioles while sparing the smaller respiratory bronchioles.^[14]

There are different ways to obtain lung tissue. A transbronchial biopsy can be done during bronchoscopy, where a thin tube with a camera is inserted through the mouth or nose into the airways, and small samples are collected. However, because obliterative bronchiolitis can be patchy, meaning it does not affect all areas equally, the transbronchial biopsy may miss the affected areas. For this reason, a surgical lung biopsy, which takes larger samples, may be needed. In children, this can sometimes be done using keyhole surgery techniques under general anesthesia.^[6]^[14]

Bronchoscopy

Bronchoscopy allows doctors to directly visualize the inside of the airways using a flexible tube with a camera. While this procedure does not definitively diagnose obliterative bronchiolitis on its own, it can help rule out other conditions and collect samples for further testing.

Differential Diagnosis

Because the symptoms of obliterative bronchiolitis overlap with many other respiratory conditions, doctors must carefully distinguish it from diseases such as asthma, chronic obstructive pulmonary disease, and other forms of bronchiolitis. One key difference is that obliterative bronchiolitis is not a disease that fills the airways with inflammatory material from the inside. Instead, it is a disease where scarring develops outside the airway wall and squeezes the tube closed. This is different from proliferative bronchiolitis or bronchiolitis obliterans organizing pneumonia, where inflammatory tissue grows inside the airways and extends into the air sacs.^[4]^[14]

⚠️ Important

The diagnosis of obliterative bronchiolitis may take time. It is not uncommon for the condition to remain undiagnosed for months or even years after the initial lung injury occurred. This delay happens because symptoms can develop gradually and because the patchy nature of the disease can make it difficult to detect through standard testing methods.

Diagnostics for Clinical Trial Qualification

When patients with obliterative bronchiolitis are being considered for enrollment in clinical trials, specific diagnostic criteria and standardized tests are used to ensure that participants truly have the disease and that their condition can be accurately monitored throughout the study.

Bronchiolitis Obliterans Syndrome Staging

For patients who have undergone lung transplantation, a specific diagnostic framework called bronchiolitis obliterans syndrome (BOS) is used. This syndrome refers to the progressive decline in lung function that occurs as a result of chronic rejection. The diagnosis is based on spirometry measurements, specifically the forced expiratory volume in one second (FEV1), which is the amount of air a person can forcefully exhale in one second.^[2]^[3]

The disease is staged based on how much the FEV1 has declined from the patient’s best measurements after transplant. Clinical trials often require that patients meet specific BOS stage criteria for enrollment. A lung function test called spirometry is used to determine the severity of the disease, and staging helps researchers understand which patients might benefit from experimental treatments and allows them to track whether the treatment is slowing the progression of the disease.^[3]

Baseline Pulmonary Function Testing

Before a patient can be enrolled in a clinical trial, comprehensive baseline pulmonary function testing is typically performed. This establishes a starting point against which future measurements can be compared. These tests not only include spirometry but may also include measurements of lung volumes, gas exchange capacity, and exercise tolerance. Having these baseline values is critical for determining whether an experimental treatment is having any effect.^[2]

Standardized Imaging Protocols

Clinical trials often require high-resolution CT scans performed according to specific protocols. This ensures that all participants have comparable imaging studies that can be reliably evaluated. The scans must include both inspiratory and expiratory phases, and specific technical parameters may be mandated to ensure consistency across different medical centers participating in the trial.

Histological Confirmation

Some clinical trials may require histological confirmation of the diagnosis through lung biopsy. This is particularly true for trials testing treatments for non-transplant-related obliterative bronchiolitis. The biopsy must show the characteristic features of constrictive bronchiolitis, including concentric fibrosis around the bronchioles and narrowing or obliteration of the airway lumens. Pathologists reviewing the samples for clinical trial purposes often use standardized scoring systems to grade the severity of the disease.^[14]

Exclusion of Other Conditions

Clinical trials typically require that other lung diseases be ruled out before a patient can participate. This might involve additional testing such as bronchoscopy with bronchoalveolar lavage (washing out cells and fluid from the lungs for analysis) to exclude active infection or other inflammatory processes. Blood tests may be performed to check for autoimmune markers or to rule out systemic conditions that could complicate interpretation of trial results.

Biomarker Measurements

Some research studies investigating new treatments for obliterative bronchiolitis may include measurement of specific biomarkers—substances in blood or other body fluids that indicate disease presence or severity. While no specific biomarker is currently standard for diagnosing obliterative bronchiolitis, research trials may explore inflammatory markers, immune system proteins, or genetic factors that could help predict disease progression or treatment response.

Prognosis and Survival Rate

Prognosis

The outlook for people with obliterative bronchiolitis varies considerably depending on the cause and severity of the disease. Some individuals may have mild impairment with slow or stable progression, while others experience rapid decline. The disease is not reversible, meaning the scarring and narrowing of the airways cannot be undone. However, treatments can sometimes slow further worsening and help manage symptoms.^[5]

For lung transplant recipients who develop bronchiolitis obliterans syndrome, the condition represents the most common type of chronic rejection and significantly impacts long-term survival. The majority of long-term lung transplant survivors will develop some degree of this syndrome. The disease can progress in stages, but not in the same way for everyone—some people may remain in an early stage for quite some time, while others progress quickly from one stage to a more advanced stage.^[3]^[18]

In children with post-infectious bronchiolitis obliterans, the prognosis depends on the severity of the initial lung injury. Usually, the condition does not continue to worsen over years, as most of the lung damage occurs during the time immediately following the infection. Some children have a mild form and can live without significant breathing problems or limitations to daily activities, while others may have more severe disease requiring ongoing oxygen therapy or other breathing support.^[20]

Some forms of bronchiolitis obliterans, particularly those following lung transplant, can be fatal if not treated. Overall, outcomes are often described as poor in severe cases, with many people experiencing progressive decline leading to death within months to years. However, the range of outcomes is wide, and factors such as early detection, removing exposure to causative agents, and appropriate treatment can influence the course of the disease.^[4]^[12]

Survival Rate

Specific survival statistics for obliterative bronchiolitis vary depending on the underlying cause. For lung transplant recipients, more than 50 percent will develop some degree of bronchiolitis obliterans by five years after transplant, and about 75 percent by ten years following transplantation. This condition is a major factor limiting long-term survival after lung transplant.^[4]^[7]

For recipients of hematopoietic stem cell transplantation (bone marrow transplant), approximately 5 to 14 percent develop bronchiolitis obliterans syndrome. When it occurs in this population, it represents a form of graft-versus-host disease affecting the lungs and can appear several months to years after transplantation.^[2]^[7]

In the general population outside of transplant recipients, obliterative bronchiolitis remains rare, and specific survival data are limited. The prognosis for occupational exposure cases, such as those related to chemical inhalation, depends heavily on early recognition, removal from exposure, and prompt treatment. The condition’s rarity makes it difficult to provide precise survival statistics for all causes, but the disease is generally considered serious with variable but often guarded long-term outcomes.^[4]

#1 Clinical Trials Search in Europe